Bibliography
- LOTVALL J: Pharmacological similarities and differences between 32-agonists. Respir. Med. (2001) 95(Suppl.B):S7–S11.
- JACK D: Safety by design. Drug Sal (1990) 5(Suppi.1):4–23.
- ••The strategy underlying the design of 132 agonists.
- COLEMAN RA, JOHNSON M, NIALS AT, VARDEY CJ: -P.,osites: their current status, and their relevance to the duration of action of long-actingp2-adrenoceptor agonists. Trends Phannacol Sci. (1996) 17(9):324–330.
- ••Review underlying how salmeterol, andsimilar compounds, have a prolonged duration of action.
- ANDERSON GP: Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective P2-adrenoceptor agonist bronchodilator. Life Se/. (1993) 52(26):2145–2160.
- HANDLEY DA: Single-isomer 3-agonists. Pharmacotherapy (2001) 21(3 Pt 2):215–275.
- Novartis looks ahead to continued dynamic launch programme of innovative new medicines. Novartis AG Press release, 17 October (2002).
- KIKKAWA H, NAITO K, IKEZAWA K: Tracheal relaxing effects and 32-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea pig tissues. Jpn.J Pharmacol (1991) 57(2):175–185.
- WEERSINK EJ, POSTMA DS, KOETER GH et al.: Picumeterol: dissociation of improvement in lung function and reduction of airways hyperresponsiveness in asthmatics Br. Clin. Phannacol. (1997) 43 (2): 169–176.
- BARROW A, CAMP SJ, DAYAL S et al: Kinetics and disposition of picumeterol in animals. Xenobiotica (1995) 25(9):993–1007.
- Theravance and GlaxoSmithKline form alliance to devlop next generation respiratory medicines. GlaxoSmithKline Press release, 6 January (2003).
- http://www.chiesigroup.com/news/ news_detail_eng.asp?id41
Websites
- http://www. gsk. com/financial/ product_pipeline. htm